K Navigator: an AI co-pilot transforming biomedical research
K Navigator, a new AI-powered research co-pilot, is set to transform biomedical science by helping researchers explore complex data and accelerate discoveries.
List view / Grid view
News
Targeting the clock: new drug disrupts glioblastoma stem cells
Scientists have developed a new drug, SHP1705, that targets hijacked circadian clock proteins used by glioblastoma stem cells to grow and resist treatment.
New data: Visugromab targets ADC resistance mechanism
CatalYm announces new preclinical data showing that its clinical-stage antibody, visugromab, can overcome resistance to antibody-drug conjugates (ADCs), showing potential to restore anti-tumour immune responses in solid tumours.
Enedra secures funding to advance AI-driven cancer platform
Enedra Therapeutics has secured new funding to advance its AI-driven CASPAROV platform, aimed at developing therapies for difficult-to-treat cancers
High-throughput NaV1.9 assay to advance pain therapies
Metrion Biosciences has introduced a breakthrough NaV1.9 screening assay, aimed at overcoming historical challenges in pain research and advancing the development of non-opioid treatments.
New enzyme tech offers hope for mitochondrial disease treatment
Japanese researchers have developed a new enzyme technology that can precisely alter the levels of mutated mitochondrial DNA in patient-derived stem cells, offering a promising new approach for treating mitochondrial disorders.
Eli Lilly backs Creyon’s quantum chemistry platform in $1B RNA drug deal
The partnership allows for the further development of AI-designed RNA-targeted therapies for a range of diseases.
New plasma therapy fights aggressive soft tissue cancer
Researchers at Osaka Metropolitan University have found that plasma-activated medium (PAM) significantly reduces synovial sarcoma tumour growth in both lab and animal models, offering a promising new approach for treating this rare and aggressive cancer.
Scientists develop immunotherapy to disarm fat-fuelled tumours
A new study reveals how tumours hijack fat metabolism to suppress immune responses - and how a novel antibody, PLT012, may reverse this effect, offering new hope for treating immunotherapy-resistant cancers.
New dual-targeting strategy shows promise in treating pancreatic cancer
Researchers at the University of Michigan have discovered a powerful combination therapy that eradicates pancreatic tumours in preclinical models, offering hope for new treatments against one of the most treatment-resistant cancers.
Blocking nitrosylation boosts treatment for NRAS melanoma
Researchers at Moffitt Cancer Center have discovered that blocking a chemical process called nitrosylation can make aggressive NRAS-mutant melanoma more responsive to treatment.
Targeting inflammation to treat atherosclerosis and MASH
A glycine-based compound developed at the University of Michigan, originally designed to treat severe fatty liver disease, has shown powerful effects in reducing atherosclerosis and vascular calcification in animal models.
Repurposed anti-inflammatory drug may help treat alcohol use disorders
A new study by Scripps Research reveals that apremilast, an FDA-approved anti-inflammatory drug, may help reduce both alcohol consumption and pain sensitivity, offering a potential dual therapy for alcohol use disorder.
Targeting zombie cells: a new treatment for chronic back pain
McGill University researchers have found that two drugs can eliminate senescent “zombie cells” in spinal discs, offering a potential new treatment for chronic low back pain.
New liver organoids research brings hope for drug development
Researchers at Keio University have developed long-lasting, functional human liver organoids from frozen hepatocytes, marking a huge moment in organoid science.
